Clinical Trials on Polyarticular-course Juvenile Idiopathic Arthritis (JIA) in Switzerland

Total 3 results

Novartis Pharmaceuticals
Pediatric Rheumatology International Trials Organization

Completed

Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) (β-SPECIFIC 2)

Systemic Juvenile Idiopathic Arthritis With Active Flare

United States, Argentina, Canada, Switzerland, Germany, Israel, South Africa, Belgium, Italy, Spain, France, Brazil, Turkey, Hungary, Poland, Norway, Sweden, Netherlands, Peru
Novartis Pharmaceuticals
International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Southwest...

Terminated

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) (β-SPECIFIC 1)

Systemic Juvenile Idiopathic Arthritis

United States, Argentina, Canada, Switzerland, Germany, United Kingdom, Israel, South Africa, Belgium, Greece, Italy, Spain, France, Brazil, Turkey, Hungary, Poland, Norway, Sweden, Netherlands, Peru, Denmark
Novartis Pharmaceuticals
Pediatric Rheumatology International Trials Organization

Completed

An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever. (β-SPECIFIC 3)

Systemic Juvenile Idiopathic Arthritis

Italy, United States, Belgium, Germany, Greece, Russian Federation, Turkey, Spain, France, Israel, Canada, Hungary, Switzerland, United Kingdom, Brazil, Austria, Sweden, Netherlands, Argentina, Peru, Poland

Clinical Trials on Polyarticular-course Juvenile Idiopathic Arthritis (JIA) in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations